Synthesis and pharmacological profile of new 1,3-disubstituted cyclohexanes as leukotriene B4 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 19, 1996, Pages 2349-2354

  Poudrel, J M ^b   Hullot, P ^b   Vidal, J P ^b   Girard, J P ^b   Rossi, J C ^b   Mulle, A ^a   Bonne, C ^a  

^a CNRS   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXY 3 (7 PHENYL 1 HEPTENYL) 1 CYCLOHEXANEACETIC ACID; CYCLOHEXANE DERIVATIVE; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOTAXIS; CHIRALITY; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EDEMA; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG; NEUTROPHIL; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SMOOTH MUSCLE CONTRACTION; TOPICAL DRUG ADMINISTRATION;

EID: 0030575617     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00424-6     Document Type: Article

References (37)

1. 1. Ford-Hutchinson, A.W.; Bray, M.A.; Doig, M.V.; Shipley, M.E., Smith, M.J.H. Nature 1980, 286, 264.
2. 2. Ringertz, B.; Palmblad, J.; Radmark, O.; Malmsten, C. FEBS Lett. 1982, 147, 180.
3. 3. Rae, S.A.; Smith, M.J.H. J. Pharm. Pharmacol. 1981, 33, 616.
4. 4. Flohé, L.; Gunzler, W. A.; Loschen, G.; Günzler, W. A. In Superoxide and superoxide dismutase in chemistry, biology and medecine; Sies, E., Ed.; Elsevier Science Publishers: Amsterdam, 1986, p 376
5. 5. Camp, R.D.R.; Coutts, A.A.; Greaves, M.W.; Kay, A.B.; Walport, M. J. Br. J. Pharmacol. 1983, 80, 497.
6. 6. Klickstein, L.B.; Spagleigh, C.; Goetzl, E. J. J. Clin. Invest. 1980, 66, 1166.
7. 7. Brain, S.; Camp, R.; Dowd, P.; Kobza-Black, A.; Greaves, M. J. Invest. Dermatol. 1984, 83, 70.
8. 8. Sharon, P.; Stenson, W. F. Gastroenterology 1984, 86, 453.
9. 9. O'Driscoll, B.R.; Cromwell, O.; Kay, A.B. Clin. Exp. Immunol. 1984, 55, 397.
10. 10. Daines, R.A.; Chambers, P.A.; Eggleston, D.S.; Foley, J.J.; Griswold Don, E.; Haltiwanger, R.C.; Jakas, D.R.; Kingsbury, W.D.; Martin, L. D.; Pendrak, I.; Schmidt, D.B.; Tzimas, M.N.; Sarau, H. J. Med. Chem. 1994, 37, 3327.
11. 11. Gapinski, D.M.; Mallett, B.E.; Froekich, L.L.; Jackson, W.T. J. Med. Chem. 1990, 33, 2798.
12. 12. Djuric, S.W.; Collins, P.W.; Jones, P.H.; Shone, R.L.; Tsai, B.S.; Fretland, D.J.; Butchko, G.M.; VillaniPrice, D.; Keith, R.H.; Zemaitis, J.M.; Metcalf, L.; Bauer, R.F. J. Med. Chem. 1989, 32, 1145.
13. 13. Namiki, M.; Iganashi, Y.; Sakamato, K.; Koga, Y. Biochem. Biophys. Res. Commun. 1986, 138, 540.
14. 14. Morris, J., Wishka, D.G. Tetrahedron Lett. 1988, 29, 143.
15. 15. (a) Konno, M.; Sakuyama, S.; Nakae, T.; Hamanaka, N.; Miyamoto, T.; Kawasaki, A. Adv. Prostaglandin, Thromboxane & Leukotriene Res. 1991, 21, 411.
16. (b) Kashikawa, K.; Tateishi, T.; Maruyama, T.; Seo, R.; Toda, M.; Miyamoto, T. Prostaglandins 1992, 44, 261.
17. 16. Huang, F.; Chan, W.; Warus, J.D.; Morrissette, M.M.; Moriarty, K. J.; Chang, M.N.; Travis, J.J.; Mitchell, L.S.; Nuss, G. W.; Sutherland, C.A. J. Med. Chem. 1992, 35, 4253.
18. th International Conference on Prostaglandins and related Compounds, Florence, 1994, June 6-10, Abstract p. 43.
19. 13C NMR, IR, elemental analysis and/or high resolution mass spectra data. Diastereomeric mixtures of compounds 1, 2, 3 and 4 were not separated, except 1d.
20. 19. Takacs, J.M.; Helle, M.A.; Seely, F.L. Tetrahedron Lett. 1986, 27, 1257.
21. 20. House, H.O.; Latham, R.A.; Slater, C.D. J. Org. Chem. 1966, 31, 2667.
22. trans = 15.9 Hz.
23. 22. Gemal, A.L; Luche, J.L. J. Am. Chem. Soc. 1981, 103, 5454.
24. 23. Huet, F.; Lechevallier, A.; Pellet, M.; Conía, J.M. Synthesis 1978, 63.
25. 24. Kugel, C.; Lellouche, J.P.; Beaucourt, J.P.; Niel, G.; Girard, J.P.; Rossi, J.C. Tetrahedron Lett. 1989, 30, 4947.
26. 3′ are more deshelded when the hydroxyl function is loocked in axial position.
27. 3): 0.85 - 1.80 (m; 14H); 1.26 (t; 3H; J = 7.1 Hz); 2.41 (s; 2H); 2.42 (m; 1H); 2.59 (t; 2H; J = 7.7 Hz), 4.00 (q; 1H; J = 6.4 Hz); 4.16 (q; 2H; J = 7.1 Hz); 5.40 (dd; 1H; J= 15.5 Hz, J = 6.7 Hz); 5.52(dd; 1H; J = 15.5 Hz, J = 6.4 Hz); 7.15 (m; 3H); 7.25 (m; 2H);
28. 27. Column used: Chiralcel® OD (Daicel), 20 μm, 250×50 mm. UV detection at 210 nm. Elution (100 ml/min) with heptane/isopropanol (90/10) afforded successively the enantiomers 1d1 (13 min) and 1d2 (21 min).
29. 28. Lin, A.H.; Ruppel, P.L., Gorman, R.R. Prostaglandins 1984, 28, 837.
30. 29. Miller, W.L.; Weeks, J. R.; Lauderdale, J.W.; Kirton, K.T. Prostaglandins 1975, 9, 9.
31. 30. Hansson, G.; Lindgren, J.A.; Dahlens, S.E.; Hedquist, P.; Sammuelsson, B. FEBS Lett. 1981, 130, 107.
32. 4 and competitors in Hank's buffer were added to the bottom half of Boyden-Keller chambers; two 3 μm cellulose nitrate filters were placed over each well and the top part of the chambers was filled with cell suspension. The chambers were incubated at 37°C for 150 min. Radioactivity on the lower filter was measured by liquid scintillation spectrometry.
33. 4 (30 nM) stimulation.
34. 33. Tsai, B.S.; Keith, R.H.; Villani-Price, D.; Haack, R.A.; Djuric, S.W. J. Pharm. Exp. Ther., 1994, 268, 1493.
35. 34. Kingsbury, W.D.; Pendrak, I.; Leber, J.D.; Boehm, J.C.; Mallet, B.; Sarau, H.M.; Foley, J.J.; Schmidt, D.B.; Daines, R.A. J. Med. Chem. 1993, 36, 3308.
36. 35. Inoue, H.; Mori, T.; Shibata, S.; Koshihara, Y. Br. J. Pharmacol. 1989, 96, 204.
37. 36. Evaluations of cycloxygenase/lipoxygenase activities have been performed by Fournier and Servier Pharmaceutical Companies, according to the methods described by Bonne, C.; Muller, A.; Latour, E.; Tissie, G; Emerit, I.; Modat, G.; Dornand, J.; Roche, M.; Giroud, J.P.; Griswold, D.E.; Marshall, P.J., Coquelet, C. Arzneim. Forsch., Drug Res. 1989, 39, 1242.